Bryan Oronsky - Concepedia

Author

Bryan Oronsky

University of California San Diego ORCID

Also Known As

B Oronsky, B T Oronsky, B. Oronsky, Bryan Oronsky, Bryan T Oronsky, Bryan T. Oronsky, Bryan. Oronsky, EpicentRx

190

Publications

Citations

H-Index

Concepts

All Affiliations

University of California San Diego Walter Reed National Military Medical Center Stanford University La Jolla Bioengineering Institute Epicentre (South Africa)

About

Bryan Oronsky is an author at University of California San Diego specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	29	704
2	Health Sciences	3	3	49
3	Biomolecular Engineering	2	2	29
4	Natural Sciences	1	1	39
5	Biochemistry	1	1	24

Bryan Oronsky

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Dinitroazetidines Are a Novel Class of Anticancer Agents and Hypoxia-Activated Radiation Sensitizers Developed from Highly Energetic Materials Shoucheng Ning, Mark D. Bednarski, Bryan Oronsky, Cancer Research	2012	101
Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study Tony Reid, Bryan Oronsky, Jan Scicinski, The Lancet Oncology Advanced CancerDose-escalation Phase 1MedicineCancer ManagementPathology	2015	90
Six Degrees of Separation: The Oxygen Effect in the Development of Radiosensitizers Bryan Oronsky, Susan J. Knox, Jan Scicinski Translational Oncology	2011	89
A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells Deepika Sharma Das, Arghya Ray, Abhishek Das, Leukemia Overcomes Drug ResistanceMedicineApoptosisCell DeathMultiple Myeloma Cells	2016	84
Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity Hongjuan Zhao, Shoucheng Ning, Jan Scicinski, Oncotarget	2015	52
REPLATINUM Phase III Randomized Study: RRx-001 + Platinum Doublet Versus Platinum Doublet in Third-Line Small Cell Lung Cancer Bryan Oronsky, Tony R. Reid, Christopher Larson, Future Oncology Platinum DoubletMedicineMetronomic TherapyPhase Iii TrialObjective Response Rate	2019	49
The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry Hongjuan Zhao, Shoucheng Ning, Rosalie Nolley, Clinical Epigenetics	2017	44
Nucleocapsid as a next-generation COVID-19 vaccine candidate Bryan Oronsky, Christopher Larson, Scott Caroen, International Journal of Infectious Diseases VaccinationSpike ProteinVaccine DevelopmentVaccine TargetVaccine Surveillance	2022	41
Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development Bryan Oronsky, Xiaoning Guo, Xiaohui Wang, Journal of Medicinal Chemistry Tumor Targeted CytotoxicityImmunologyPathologyPharmacotherapyCancer Biology	2021	39
Novel nitric oxide generating compound glycidyl nitrate enhances the therapeutic efficacy of chemotherapy and radiotherapy Shoucheng Ning, Mark D. Bednarski, Bryan Oronsky, Biochemical and Biophysical Research Communications Compound GlycidylOncologyReactive Nitrogen SpecieMedicineTherapeutic Efficacy	2014	38

Page 1